Documentation
Description:
IoN is a multicentre phase II/III asking is ablative radioiodine necessary for low risk differentiated thyroid cancer patients.
560 patients will be recruited and randomised 1:1 to receive radioiodine ablation or no ablation.
Samples collected during trial: Stimulated Tg blood samples for patients taken at the treatment visit, 2 months post treatment, 6-9 months post treatment and every 6 months thereafter for 5 years.
Coverage
Spatial:
United Kingdom,England
Provenance
Temporal
Start Date:
01 January 2012
Time Lag:
Variable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided.
Access Request Cost:
Not specified
Delivery Lead Time:
Not applicable
Data Controller:
University College London
Usage
Resource Creators:
In Progress
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Languages:
en
Formats:
In Progress